**Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi – a systematic review and economic evaluation**


**Record Status**
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

**Citation**

**Authors' objectives**
To determine the clinical effectiveness and cost-effectiveness of three tests [LightCycler SeptiFast Test MGRADE® (Roche Diagnostics, Risch-Rotkreuz, Switzerland); SepsiTest™ (Molzym Molecular Diagnostics, Bremen, Germany); and the IRIDICA BAC BSI assay (Abbott Diagnostics, Lake Forest, IL, USA)] for the rapid identification of bloodstream bacteria and fungi in patients with suspected sepsis compared with standard practice (blood culture with or without matrix-absorbed laser desorption/ionisation time-of-flight mass spectrometry).

**Authors' conclusions**
The clinical effectiveness and cost-effectiveness of the interventions cannot be reliably determined with the current evidence base. Appropriate studies, which allow information from the tests to be implemented in clinical practice, are required.

**Project page URL**
http://www.nets.nihr.ac.uk/projects/hta/146904

**Final publication URL**
http://www.journalslibrary.nihr.ac.uk/hta/hta20460/#/abstract

**Indexing Status**
Subject indexing assigned by CRD

**MeSH**
Humans; Bacteria; Cost-Benefit Analysis; Fungi; Sepsis; Diagnostic Techniques and Procedures

**Language Published**
English

**Country of organisation**
England

**English summary**
An English language summary is available.

**Address for correspondence**
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk
Accession Number
32016000829

Date abstract record published
29/06/2016